Search company, investor...
Search
Inversago Pharma company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

inversago.com

Founded Year

2015

Stage

Series B | Alive

Total Raised

$40.34M

Last Raised

$35M | 2 yrs ago

About Inversago Pharma

Inversago Pharma is a specialized, preclinical-stage biotech company that develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome (PWS), Type-1 Diabetes (T1D), obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH).

Inversago Pharma Headquarters Location

1010 Sherbrooke Ouest Suite 1800

Montreal, Quebec, H3A 2A7,

Canada

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Inversago Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Inversago Pharma is included in 3 Expert Collections, including Cannabis.

C

Cannabis

3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

D

Diabetes

1,750 items

Latest Inversago Pharma News

Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease

Sep 15, 2022

- FDA clears IND of First-In-Class, Peripherally-Acting CB1 Inverse Agonist INV-202 - Phase 2 trial in Diabetic Kidney Disease will also provide data in complications of diabetes, metabolic syndrome and dyslipidemia September 15, 2022 08:00 AM Eastern Daylight Time MONTREAL--( BUSINESS WIRE )--Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, has received FDA clearance of its Investigational New Drug (IND) application for a phase 2 study in Diabetic Kidney Disease (DKD) for INV-202, the Company’s lead program. Inversago scientists identified Diabetic Kidney Disease as the most promising indication for a Phase 2 study, given its important unmet medical need. Such a study presents an opportunity to evaluate a comprehensive set of biomarker data in DKD that may also be relevant to a broad landscape of diabetic-related indications, including cardiometabolic and fibrotic complications. INV-202, which is presently completing Phase 1b studies in patients with metabolic syndrome, showed a favorable profile in a first-in-human study, including safety and tolerability, oral absorption, and pharmacokinetics. It also demonstrated potential for decreased appetite, a relevant pharmacodynamic marker of early efficacy of Inversago’s lead program. Dr. Glenn Crater, CMO at Inversago, stated: “This IND clearance is an important milestone for Inversago and marks the beginning of an important regulatory and clinical process in bringing a new therapeutic approach to patients suffering from Diabetic Kidney Disease.” “We are excited to report this significant achievement for our first-in-class, peripherally-acting CB1 inverse agonist, which confirms our leadership in this field. We believe that CB1 blockers, such as INV-202, offer opportunities in multiple therapeutic areas,” added François Ravenelle, PhD, Chief Executive Officer of Inversago. Inversago believes that peripheral CB1 blockade, either alone or in combination with other therapies, represents an opportunity to address the significant unmet medical need of DKD. As obesity, diabetes and their complications continue to affect more people around the world, the need for new therapies will only continue to grow. About INV-202 INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of a range of cardiometabolic and fibrotic conditions, including Diabetic Kidney Disease. It is specifically designed to preferentially block CB1 receptors in peripheral tissues such as the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs. The therapeutic effects of a peripheral CB1 blockade in a range of cardiometabolic and fibrotic diseases are well-documented, paving the way for potential treatment of a large number of patients with current unmet needs. About Diabetic Kidney Disease Diabetic Kidney Disease (DKD) occurs when diabetes causes damage to the glomeruli and proximal renal tubules that are essential to blood filtering and waste elimination. As a complication of type 1 and type 2 diabetes, diabetic nephropathy affects approximately 1 in 3 people living with diabetes in the United States. No cure exists for this indication and available medications only help slowing the progression of the disease. Like other chronic diseases, it is expected that multiple mechanisms are needed to achieve adequate control of this progressive disease. Inversago believes that peripheral CB1 blockade represents a promising therapeutic avenue for such a metabolic disorder. About Inversago Pharma Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. For more information, visit inversago.com . Contacts

Inversago Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Inversago Pharma Rank

  • When was Inversago Pharma founded?

    Inversago Pharma was founded in 2015.

  • Where is Inversago Pharma's headquarters?

    Inversago Pharma's headquarters is located at 1010 Sherbrooke Ouest, Montreal.

  • What is Inversago Pharma's latest funding round?

    Inversago Pharma's latest funding round is Series B.

  • How much did Inversago Pharma raise?

    Inversago Pharma raised a total of $40.34M.

  • Who are the investors of Inversago Pharma?

    Investors of Inversago Pharma include AQC Capital, JDRF T1D Fund, AmorChem, Genesys Capital, adMare BioInnovations and 7 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.